INS and type 2 diabetes mellitus: This evidence has been shown by several in vitro and in vivo animal models [324,325,326] and in humans [325,327,328] to increase the bioavailability of NO to reduce vascular tone, blood pressure, and micro- and macrovascular complications, and improving insulin sensitivity is certainly an attractive therapeutic target in T2D.